Jump Financial LLC Boosts Stock Holdings in Pfizer Inc. $PFE

Key Points

• Jump Financial LLC significantly increased its stake in Pfizer Inc. by 305.1%, acquiring 949,651 shares during the first quarter, bringing its total to 1,260,938 shares valued at approximately $31.95 million.
• Multiple large investors including Brighton Jones LLC and Revolve Wealth Partners LLC have also made substantial increases in their holdings of Pfizer stock, reflecting a general trend of institutional investment in the company.
• Despite recent positive earnings reports, analyst ratings on Pfizer are mixed, with an average rating of "Hold" and a consensus target price of $28.12.

Jump Financial LLC lifted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 305.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,260,938 shares of the biopharmaceutical company's stock after buying an additional 949,651 shares during the period. Jump Financial LLC's holdings in Pfizer were worth $31,952,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC raised its stake in Pfizer by 21.7% during the first quarter. Smartleaf Asset Management LLC now owns 28,575 shares of the biopharmaceutical company's stock worth $720,000 after purchasing an additional 5,086 shares during the period. RBO & Co. LLC purchased a new stake in shares of Pfizer in the 1st quarter valued at approximately $750,000. Haverford Trust Co grew its holdings in shares of Pfizer by 22.3% in the first quarter. Haverford Trust Co now owns 440,875 shares of the biopharmaceutical company's stock valued at $11,172,000 after purchasing an additional 80,495 shares in the last quarter. Groupe la Francaise grew its holdings in shares of Pfizer by 13.5% in the first quarter. Groupe la Francaise now owns 162,213 shares of the biopharmaceutical company's stock valued at $3,971,000 after purchasing an additional 19,291 shares in the last quarter. Finally, AlphaQuest LLC grew its holdings in shares of Pfizer by 38.3% in the first quarter. AlphaQuest LLC now owns 33,304 shares of the biopharmaceutical company's stock valued at $844,000 after purchasing an additional 9,221 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have commented on PFE. Bank of America boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Morgan Stanley boosted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Redburn Atlantic lowered their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. Leerink Partners lowered their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Finally, Berenberg Bank lowered their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Stock Performance

PFE stock traded down $0.73 on Monday, hitting $25.15. The company's stock had a trading volume of 32,304,503 shares, compared to its average volume of 45,249,543. The firm has a 50 day moving average of $24.70 and a two-hundred day moving average of $24.39. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The stock has a market cap of $142.99 billion, a price-to-earnings ratio of 13.38, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the firm earned $0.60 EPS. Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer's dividend payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.